Dr. Claude Carignan

Professor

Build a Statement of Purpose

Generate a tailored SOP for Dr. Claude Carignan. Improve your application with a focused, well-structured draft.

Biography

Claude Carignan has been a professor in the Department of Physics since 1985, specializing in dark matter with a focus on galactic and extragalactic astronomy. Throughout his career, he has engaged with various national organizations such as the Research Centre of the Mont Mégantic Observatory and the Canadian Astronomical Society (CASCA). His work has reached international dimensions, contributing to the Office Astronomy Development and the African Astronomical Society. In 2006, he established an astrophysics program at the University of Ouagadougou, drawing inspiration from the program at Université de Montréal, an achievement that earned him the Internationalist Award from CÉRIUM in 2009. Currently, he holds the SKA Chair in Extragalactic Multi-wavelength Astronomy at the University of Cape Town, aiming to promote the construction of one of the world's largest telescopes. His research contributions over the last twenty years elucidate the mass distribution in dwarf galaxies, demonstrating a more substantial dark matter presence (~90%) compared to massive spiral galaxies (~50%). His findings have been instrumental in revealing the distinctive role of dark matter across various galactic structures, proving the necessity of refined observational techniques and simulations in astrophysics.

Research Interests

Requirements for Université de Montréal

Doctorate Program
Requirements
GPA Requirement
Required:3.3
TOEFL
Listening
Required:20
Reading
Required:20
Writing
Required:20
Speaking
Required:20
Total
Required:90
Prerequisites
MSc in Pharmacology or equivalent Research supervisor confirmation
Application Checklist
  • Transcripts
  • Birth certificate
  • Curriculum Vitae
  • Proof of French proficiency (B2/C1)
Specialization Notes

Department of Pharmacology and Physiology - Research intensive with options in Neuropharmacology and Pharmacogenomics.